Clinical trials: Motor Activity
Weight Loss
Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults
The purpose of this study is to examine the feasibility of a campaign intervention for weight management compared to a standard behavioral weight loss intervention in overweight and obese adults.
- Trial name
- NCT01803737
- Testing
- Standard Behavioral Weight Loss Intervention (SBWL), Campaign Intervention (CI)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pittsburgh
Alzheimer's Disease
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
- Trial name
- NCT01735630
- Testing
- ELND005
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- OPKO Health, Inc.
Motor Activity
Be a Champion! Comprehensive School Physical Activity Program
The purpose of this project is to develop a Comprehensive School Physical Activity Program (CSPAP) training protocol, and test the feasibility, acceptability, and effectiveness of its delivery in an elementary school setting.
- Trial name
- BAC! (NCT02465372)
- Testing
- CSPAP
- Where
- United States
- Volunteers
- 599 people
- Sponsor
- Wake Forest University Health Sciences
Arthritis, Rheumatoid
Effects of a Mobile Application RA Joint Protection and Activity Self-management Program
The goal of this clinical trial is to evaluate the effectiveness of mobile application self-management program (App) for joint protection and physical activity in patients with rheumatoid arthritis.
- Trial name
- NCT05570175
- Testing
- Mobile application RA joint protection and activity self-management program
- Where
- Taiwan
- Volunteers
- 46 people
- Sponsor
- Chang Gung Memorial Hospital
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Parkinson's Disease, Drug-induced Parkinsonism
Effect of Exercise in Parkinsonism
Parkinson's disease (PD) is a common neurodegenerative disorder affecting approximately 80,000 Veterans, representing a priority area for VA research.
- Trial name
- NCT02598973
- Testing
- Exercise
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Hepatocellular Carcinoma
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or…
- Trial name
- NCT02519348
- Testing
- Tremelimumab, Durvalumab, Bevacizumab
- Where
- 44 sites in United States, China and 7 more
- Volunteers
- 433 people
- Sponsor
- MedImmune LLC
Social Isolation, Aging
A Personalized Health Behavior System
The objectives of this study are to examine the usability and efficacy, for diverse older adults, of a new tablet-based dynamic system: the Fittle Senior System (FSS) that will provide: (1) personalized behavior-change programs…
- Conditions
- Social Isolation, Aging, Physical Activity
- Trial name
- FITTLESenior (NCT03538158)
- Testing
- Intervention Condition, Control Condition
- Where
- 2 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Rheumatoid Arthritis
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
To assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (ETN) + methotrexate (MTX) with usual disease-modifying anti-rheumatic drug (DMARD) treatment in subjects with moderate RA who were treated…
- Trial name
- NCT00706797
- Testing
- etanercept (EnbrelTM), methotrexate
- Where
- 45 sites in Czechia, France and 7 more
- Volunteers
- 141 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Physical Activity
Classroom Activities
Movement integration programs that incorporate physical activity into academics are widely available for teachers to use, and have been shown to provide meaningful amounts of physical activity, improve on-task behavior, enhance…
- Trial name
- NCT03394846
- Testing
- Test of Existing MI Products
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Cancer
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
This was a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors.
- Trial name
- NCT02124772
- Testing
- Trametinib, Dabrafenib
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Physical Activity
Development and Feasibility of an Incentive Scheme to Promote Walking/Cycling to School
The aim of this study is to investigate whether an incentive scheme is a feasible approach to increase walking/cycling to school.
- Trial name
- RIGHT_TRACKS (NCT02282631)
- Testing
- Incentive scheme
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Newcastle University
NSCLC, Stage IV, NSCLC Stage IIIB
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Open-label, Phase 2, single treatment arm, 3 cohorts
- Conditions
- NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC, NSCLC, Recurrent
- Trial name
- RAIN (NCT03805841)
- Testing
- tarloxotinib bromide
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 41 people
- Sponsor
- Rain Oncology Inc
Pregnancy Related, Obesity
Monitoring Movement and Health Study
The investigators will study sedentary behavior (SED) across pregnancy in young women. We hypothesize that SED will increase across pregnancy and that higher SED will be related to worse cardiovascular health, specifically…
- Conditions
- Pregnancy Related, Obesity, Hypertension
- Trial name
- MoM Health (NCT03084302)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Pittsburgh
Alzheimer's Disease
Alzheimer's Prevention Through Exercise
The purpose of this study is to learn about the possible benefits of aerobic exercise in controlling or reducing the amount of amyloid present in the brain, reducing changes in brain structure that may lead to Alzheimer's Disease…
- Trial name
- APEx (NCT02000583)
- Testing
- Aerobic Exercise, Standard of Care
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of Kansas Medical Center
Heart Failure
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit
The purpose of this research study is to better understand how exercise training in older adults (≥65 years) with heart failure (HF) affects skeletal muscle both intrinsically and in respect to its impact on functional capacity.
- Trial name
- EXT-HF (NCT03648762)
- Testing
- Aerobic Exercise Intervention, Combined Aerobic and Strength Exercise Intervention, Inspiratory Muscle Training Exercise Intervention
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- VA Office of Research and Development
Melanoma
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
This study evaluates whether it is safe to administer a peptide vaccine in combination with pembrolizumab. This study will also evaluate the effects of the combination of the peptide vaccine and pembrolizumab on the immune…
- Trial name
- Mel64 (NCT02515227)
- Testing
- 6MHP, Pembrolizumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Craig L Slingluff, Jr
Hepatitis B
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
Normal healthy volunteer (NHV) participants will enroll sequentially into a total of 6 escalating dose levels (6 subjects per dose level), randomized to receive a single dose of ARC-521 Injection or placebo.
- Trial name
- NCT02797522
- Testing
- ARC-521 Injection, antihistamine, acetaminophen
- Where
- New Zealand
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Neuroblastoma, Rhabdomyosarcoma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor
- Trial name
- NCT01962103
- Testing
- nab-paclitaxel
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Uveal Melanoma, Choroid Neoplasm
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal…
- Trial name
- NCT02771340
- Testing
- ICON-1
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Iconic Therapeutics, Inc.